Millennium Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $90.8M | Buy |
2,256,802
+1,310,343
| +138% | +$28.2M | 0.04% | 491 |
|
|
2025
Q4 | $23.8M | Sell |
946,459
-397,267
| -30% | -$9.32M | 0.01% | 1412 |
|
|
2025
Q3 | $30.4M | Buy |
1,343,726
+1,141,274
| +564% | +$26.6M | 0.01% | 1243 |
|
|
2025
Q2 | $3.5M | Sell |
202,452
-249,521
| -55% | -$4.62M | ﹤0.01% | 3347 |
|
|
2025
Q1 | $9.88M | Sell |
451,973
-123,517
| -21% | -$3.41M | 0.01% | 2201 |
|
|
2024
Q4 | $18.4M | Buy |
575,490
+498,104
| +644% | +$15M | 0.01% | 1588 |
|
|
2024
Q3 | $2.23M | Sell |
77,386
-128,525
| -62% | -$4.76M | ﹤0.01% | 3607 |
|
|
2024
Q2 | $7.9M | Sell |
205,911
-579,485
| -74% | -$26.2M | ﹤0.01% | 2303 |
|
|
2024
Q1 | $46.2M | Buy |
785,396
+772,869
| +6,170% | +$49.3M | 0.02% | 871 |
|
|
2023
Q4 | $750K | Sell |
12,527
-32,602
| -72% | -$1.65M | ﹤0.01% | 4374 |
|
|
2023
Q3 | $1.72M | Sell |
45,129
-873,682
| -95% | -$38.4M | ﹤0.01% | 3702 |
|
|
2023
Q2 | $83.7M | Buy |
918,811
+370,610
| +68% | +$32M | 0.04% | 445 |
|
|
2023
Q1 | $36.2M | Buy |
548,201
+528,565
| +2,692% | +$30.5M | 0.02% | 902 |
|
|
2022
Q4 | $1.01M | Sell |
19,636
-238,233
| -92% | -$12.6M | ﹤0.01% | 4149 |
|
|
2022
Q3 | $17.6M | Buy |
+257,869
| New | +$15.3M | 0.01% | 1476 |
|
|
2022
Q2 | – | Sell |
-60,505
| Closed | -$2.76M | – | 6933 |
|
|
2022
Q1 | $3.07M | Sell |
60,505
-251,497
| -81% | -$11.1M | ﹤0.01% | 3476 |
|
|
2021
Q4 | $14.8M | Sell |
312,002
-93,380
| -23% | -$3.68M | 0.01% | 1730 |
|
|
2021
Q3 | $13.4M | Buy |
+405,382
| New | +$22.8M | 0.01% | 1712 |
|
|
2021
Q2 | – | Sell |
-158,571
| Closed | -$8.18M | – | 6487 |
|
|
2021
Q1 | $6.8M | Sell |
158,571
-83,143
| -34% | -$3.93M | ﹤0.01% | 2235 |
|
|
2020
Q4 | $13.8M | Sell |
241,714
-674,989
| -74% | -$28.6M | 0.01% | 1381 |
|
|
2020
Q3 | $27.7K | Sell |
916,703
-158,547
| -15% | -$4.74M | 0.03% | 608 |
|
|
2020
Q2 | $35.1M | Sell |
1,075,250
-282,336
| -21% | -$9.07M | 0.05% | 452 |
|
|
2020
Q1 | $36.4M | Buy |
1,357,586
+774,980
| +133% | +$27.5M | 0.08% | 245 |
|
|
2019
Q4 | $17.8M | Sell |
582,606
-2,128,655
| -79% | -$58.9M | 0.02% | 931 |
|
|
2019
Q3 | $65.3M | Buy |
2,711,261
+667,337
| +33% | +$18.4M | 0.1% | 219 |
|
|
2019
Q2 | $51.8M | Buy |
2,043,924
+117,358
| +6% | +$2.39M | 0.08% | 331 |
|
|
2019
Q1 | $37.6M | Buy |
1,926,566
+744,181
| +63% | +$11.7M | 0.06% | 457 |
|
|
2018
Q4 | $15.6M | Buy |
1,182,385
+75,276
| +7% | +$1.16M | 0.02% | 834 |
|
|
2018
Q3 | $19.7M | Buy |
1,107,109
+213,649
| +24% | +$3.95M | 0.02% | 850 |
|
|
2018
Q2 | $19.7M | Buy |
+893,460
| New | +$20.5M | 0.03% | 869 |
|
Other funds holding APLS
ACA
PCM
DTC
Millennium Management's APLS Position: Q1 2026 in Review
Millennium Management increased its Apellis Pharmaceuticals (APLS) stake by 138% in Q1 2026, buying an estimated $28.2M and bringing the position to 2,256,802 shares worth $90.8M. The position accounts for 0.04% of the portfolio, ranked #491.
Millennium Management first reported a position in APLS in Q2 2018 and has held it in 30 quarters since. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.
- Millennium Management held 2,256,802 shares of Apellis Pharmaceuticals worth $90.8M as of Q1 2026.
- Millennium Management bought 1,310,343 Apellis Pharmaceuticals shares in Q1 2026, an estimated $28.2M.
- Apellis Pharmaceuticals made up 0.04% of Millennium Management's portfolio in Q1 2026, its #491 holding.
- Millennium Management first reported a position in Apellis Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
- 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.